Hikma Pharmaceuticals (LON:HIK) Reaches New 1-Year High - What's Next?

Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report)'s share price reached a new 52-week high during trading on Wednesday . The company traded as high as GBX 2,356 ($29.65) and last traded at GBX 2,338 ($29.43), with a volume of 1704184 shares changing hands. The stock had previously closed at GBX 2,308 ($29.05).

Analysts Set New Price Targets

Separately, Berenberg Bank boosted their price target on Hikma Pharmaceuticals from GBX 2,400 ($30.21) to GBX 2,560 ($32.22) and gave the stock a "buy" rating in a research report on Wednesday, January 29th.

Hikma Pharmaceuticals Price Performance

The stock has a 50 day simple moving average of GBX 2,089.68 and a two-hundred day simple moving average of GBX 1,984.25. The company has a market cap of £6.36 billion, a price-to-earnings ratio of 22.49, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41. The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.